查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370929

兒科藥物市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按類型、給藥途徑、最終用戶、地區、競爭細分

Pediatric Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Route Of Administration, By End-User, By Region, By Competition
出版日期: | 出版商: TechSci Research | 英文 178 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022年，全球兒科藥品市場估值達到1,185.4億美元，在整個預測期內有望實現令人印象深刻的成長，預計到2028年年複合成長率（CAGR）為5.71%，預計將達到1,650.2億美元到2028 年。兒科藥品市場是製藥業的關鍵部門，專注於為嬰兒、兒童和青少年提供安全有效的治療。滿足年輕人的醫療保健需求需要根據他們獨特的生理和發育需求量身定做專門的藥物。隨著醫學研究的進步、監管舉措以及對解決兒童健康問題重要性的日益認知的推動，兒科藥物市場經歷了大幅成長。

美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）等監管機構透過延長獨佔權和經濟獎勵等激勵措施，鼓勵製藥公司投資兒科藥物開發。這些舉措引發了針對兒科族群的更多研發 (R&D) 努力。慢性疾病（例如氣喘、糖尿病、神經系統疾病）和傳染病（例如 COVID-19）等疾病迫使製藥公司專注於針對這些健康挑戰的客製化療法。

基因組學、藥理學和藥物傳遞方面的科學進步促進了更精確和個性化的兒科藥物的配製，從而促使增加對適合兒童的創新製劑的投資。在監管推動、科學進步以及對兒童獨特醫療保健先決條件的認知增強的推動下，兒科藥品市場持續發展。

市場概況
預測期 2024-2028
2022 年市場規模 1185.4億美元
2028 年市場規模 1650.2億美元
2023-2028 年年複合成長率 5.71%
成長最快的細分市場 網路藥局
最大的市場 北美洲

主要市場促進因素

兒童人口不斷增加

人口結構正在發生變化，兒科人口顯著增加。根據聯合國預測，到 2050 年，全球 0-14 歲人口預計將達到 22 億。這種激增凸顯了對兒科醫療保健的高度關注，推動了對兒童藥物的需求。他們獨特的生理學需要優先考慮安全性和有效性的專門治療。

兒科疾病發生率增加

雖然醫學的進步降低了兒童死亡率，但慢性病和罕見疾病的盛行率卻在上升。兒童癌症、自體免疫疾病、先天性疾病和精神健康障礙等疾病更為明顯，需要量身訂做的醫療關注和治療。

主要市場挑戰

道德和安全考慮

由於兒童的脆弱性和症狀表達的潛在困難，進行涉及未成年人的臨床試驗需要仔細的倫理指導。平衡資料收集和參與者的福祉是一個挑戰。

缺乏研發重點

從歷史上看，由於倫理問題和後勤複雜性，兒童在臨床試驗中的代表性不足。這種稀缺性阻礙了針對兒童需求而設計的有證據支持的治療的可用性。

劑量和配方的複雜性

與成人相比，兒科患者的動態生長需要不同的劑量方法和藥物形式。開發適合年齡的劑型和劑量對於避免不正確的給藥結果是複雜且至關重要的。

主要市場趨勢

技術進步

技術突破正在重塑兒科醫學，改變診斷、治療和藥物開發模式。精準醫學、藥物基因組學、數位健康技術和人工智慧 (AI) 透過增強治療客製化、真實世界證據收集和藥物發現正在徹底改變兒科醫療保健。

細分市場洞察

類型洞察

呼吸系統疾病藥物部分是主要部分，反映了兒科族群中氣喘和支氣管炎等疾病的盛行率。越來越多的人接觸過敏原、感染和環境因素，導致呼吸系統疾病日益突出。

最終用途見解

醫院因其在提供客製化兒科護理方面的專業知識而成為主要的最終用戶。專業科室和診斷工具使醫院成為綜合兒科治療的主要來源。

區域洞察

北美憑藉其強大的製藥業、研究機構和有利的監管框架，推動了兒科藥物市場的發展。 《兒科研究公平法案》(PREA) 和臨床試驗基礎設施等措施有助於促進成長。

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：COVID-19 對全球兒科藥物市場的影響

第 4 章：客戶之聲

第 5 章：執行摘要

第 6 章：全球噬菌體治療市場概述

第 7 章：全球兒科藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依類型（呼吸系統疾病藥物、自體免疫疾病藥物、胃腸道藥物、心血管藥物）
    • 依給藥途徑（口服、局部、腸外、其他）
    • 按最終使用者（醫院、專科診所、居家照護）
    • 按公司分類 (2022)
    • 按地區
  • 市場地圖
    • 按類型
    • 依給藥途徑
    • 按最終用戶

第 8 章：北美兒科藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區
  • 政策和監管環境
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 9 章：歐洲兒科藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區
  • 政策和監管環境
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 10 章：亞太地區兒科藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區
  • 政策和監管環境
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 11 章：南美洲兒科藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 給藥途徑
    • 按最終用戶
    • 按國家/地區
  • 政策和監管環境
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 12 章：中東和非洲兒科藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區
  • 政策和監管環境
  • MEA：國家分析
    • 南非 兒科藥物
    • 沙烏地阿拉伯 兒科藥物
    • 阿拉伯聯合大公國兒科藥物

第 13 章：市場動態

  • 促進要素
  • 挑戰

第 14 章：市場趨勢與發展

第15章：波特五力分析

第 16 章：全球兒科藥物市場：SWOT 分析

第 17 章：用於動物健康的市售噬菌體類型列表

第18章：競爭格局

  • 商業概覽
  • 公司概況
  • 類型和服務
  • 財務（上市公司）
  • 最近的發展
  • SWOT分析
    • BioMarin
    • Horizon Therapeutics plc
    • Gilead Sciences Inc.
    • Sumitomo Pharma Co., Ltd.
    • Jazz Pharmaceuticals, Inc.
    • GlaxoSmithKline plc.
    • Abbott
    • F. Hoffman La Roche, Ltd.
    • Boehringer Ingelheim International GmbH
    • Johnson & Johnson Services, Inc.
    • Novartis AG
    • Pfizer, Inc.

第 19 章：策略建議

第 20 章：關於我們與免責聲明

簡介目錄
Product Code: 15921

The Global Pediatric Drugs Market reached a valuation of USD 118.54 Billion in 2022, and it is poised for impressive growth throughout the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 5.71% up to 2028 and expected to reach USD 165.02 Billion by 2028. The pediatric drugs market represents a critical sector within the pharmaceutical industry, focused on delivering safe and efficacious treatments for infants, children, and adolescents. Meeting the healthcare needs of the younger demographic necessitates specialized medications tailored to their unique physiological and developmental requirements. The market for pediatric drugs has experienced substantial growth over time, driven by advancements in medical research, regulatory initiatives, and an increased recognition of the significance of addressing childhood health concerns.

Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have encouraged pharmaceutical enterprises to invest in pediatric drug development through incentives like exclusivity extensions and financial rewards. These initiatives have sparked heightened research and development (R&D) endeavors directed at pediatric populations. Conditions such as chronic ailments (e.g., asthma, diabetes, neurological disorders) and infectious diseases (e.g., COVID-19) have impelled pharmaceutical companies to concentrate on tailored therapies for these health challenges.

Scientific progress in genomics, pharmacology, and drug delivery has facilitated the formulation of more precise and individualized pediatric medications, thus prompting augmented investment in innovative formulations suitable for children. The pediatric drugs market's evolution persists, buoyed by regulatory drives, scientific advancements, and an enhanced awareness of the distinctive healthcare prerequisites of children.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 118.54 Billion
Market Size 2028USD 165.02 Billion
CAGR 2023-20285.71%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Key Market Drivers

Rising Pediatric Population

The demographic landscape is witnessing a shift, with a notable rise in the pediatric population. By 2050, the global population aged 0-14 is projected to reach 2.2 billion according to the United Nations. This surge underscores the heightened focus on pediatric healthcare, driving the demand for medications tailored to children. Their unique physiology necessitates specialized treatments that prioritize safety and efficacy.

Increasing Incidence of Pediatric Diseases

While advancements in medicine have led to reduced mortality rates among children, the prevalence of chronic and rare diseases has escalated. Conditions such as childhood cancers, autoimmune disorders, congenital diseases, and mental health disorders are more pronounced, compelling tailored medical attention and therapies.

Key Market Challenges

Ethical and Safety Considerations

Conducting clinical trials involving minors requires careful ethical navigation due to children's vulnerability and potential difficulties in symptom expression. Balancing data acquisition and participant well-being poses a challenge.

Lack of R&D Focus

Historically, children have been underrepresented in clinical trials due to ethical concerns and logistical complexities. This scarcity impedes the availability of evidence-backed treatments designed for children's needs.

Dosing and Formulation Complexity

Pediatric patients' dynamic growth necessitates distinct approaches to dosing and drug forms compared to adults. Developing age-appropriate dosage forms and dosages is intricate and crucial to avoid incorrect dosing outcomes.

Key Market Trends

Technological Advancements

Technological breakthroughs are reshaping pediatric medicine, altering diagnosis, treatment, and drug development landscapes. Precision medicine, pharmacogenomics, digital health technologies, and artificial intelligence (AI) are revolutionizing pediatric healthcare by enhancing treatment customization, real-world evidence collection, and drug discovery.

Segmental Insights

Type Insights

The Respiratory Disorder Drugs segment is the dominant segment, reflecting the prevalence of conditions like asthma and bronchitis in pediatric populations. The rising exposure to allergens, infections, and environmental factors contributes to respiratory disorders' prominence.

End-Use Insights

Hospitals are the major end-users due to their expertise in offering tailored pediatric care. Specialized departments and diagnostic tools position hospitals as the primary source of comprehensive pediatric treatment.

Regional Insights

North America, with its robust pharmaceutical industry, research institutions, and favorable regulatory framework, drives the pediatric drugs market. Initiatives like the Pediatric Research Equity Act (PREA) and clinical trial infrastructure contribute to growth.

The forecasted period presents opportunities for growth and innovation in the pediatric drugs market. The industry's response to ethical concerns, formulation complexity, and unique pediatric needs, coupled with advancements in precision medicine, digital health, collaboration, and rare disease treatment, can shape the future of pediatric healthcare positively. By embracing these challenges and capitalizing on opportunities, the pharmaceutical sector can contribute significantly to pediatric well-being and healthcare advancement.

Key Market Players

  • BioMarin
  • Horizon Therapeutics plc
  • Gilead Sciences Inc.
  • Sumitomo Pharma Co., Ltd.
  • Jazz Pharmaceuticals, Inc.
  • GlaxoSmithKline plc.
  • Abbott
  • F. Hoffman La Roche, Ltd.
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer, Inc.

Report Scope:

  • In this report, the Global Pediatric Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Pediatric Drugs Market, By Type:

  • Respiratory Disorder Drugs
  • Autoimmune Disorder Drugs
  • Gastrointestinal Drugs
  • Cardiovascular Drugs

Pediatric Drugs Market, By Route Of Administration:

  • Oral
  • Topical
  • Parenteral
  • Others

Pediatric Drugs Market, By End-Use:

  • Hospitals
  • Specialty Clinics
  • Homecare

Pediatric Drugs Market, By Region:

  • North America
  • Asia-Pacific
  • Europe
  • Middle East & Africa
  • South America

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Drugs Market.

Available Customizations:

  • Global Pediatric Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Pediatric Drugs Market

4. Voice of Customer

5. Executive Summary

6. Global Phage Therapy Market Overview

7. Global Pediatric Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs)
    • 7.2.2. By Route Of Administration (Oral, Topical, Parenteral, Others)
    • 7.2.3. By End User (Hospitals, Specialty Clinics, Homecare)
    • 7.2.4. By Company (2022)
    • 7.2.5. By Region
  • 7.3. Market Map
    • 7.3.1. By Type
    • 7.3.2. By Route Of Administration
    • 7.3.3. By End User

8. North America Pediatric Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Route Of Administration
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Policy & Regulatory Landscape
  • 8.4. North America: Country Analysis
    • 8.4.1. United States Pediatric Drugs Market Outlook
      • 8.4.1.1. Market Size & Forecast
        • 8.4.1.1.1. By Value
      • 8.4.1.2. Market Share & Forecast
        • 8.4.1.2.1. By Type
        • 8.4.1.2.2. By Route Of Administration
        • 8.4.1.2.3. By End User
    • 8.4.2. Mexico Pediatric Drugs Market Outlook
      • 8.4.2.1. Market Size & Forecast
        • 8.4.2.1.1. By Value
      • 8.4.2.2. Market Share & Forecast
        • 8.4.2.2.1. By Type
        • 8.4.2.2.2. By Route Of Administration
        • 8.4.2.2.3. By End User
    • 8.4.3. Canada Pediatric Drugs Market Outlook
      • 8.4.3.1. Market Size & Forecast
        • 8.4.3.1.1. By Value
      • 8.4.3.2. Market Share & Forecast
        • 8.4.3.2.1. By Type
        • 8.4.3.2.2. By Route Of Administration
        • 8.4.3.2.3. By End User

9. Europe Pediatric Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Route Of Administration
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Policy & Regulatory Landscape
  • 9.4. Europe: Country Analysis
    • 9.4.1. France Pediatric Drugs Market Outlook
      • 9.4.1.1. Market Size & Forecast
        • 9.4.1.1.1. By Value
      • 9.4.1.2. Market Share & Forecast
        • 9.4.1.2.1. By Type
        • 9.4.1.2.2. By Route Of Administration
        • 9.4.1.2.3. By End User
    • 9.4.2. Germany Pediatric Drugs Market Outlook
      • 9.4.2.1. Market Size & Forecast
        • 9.4.2.1.1. By Value
      • 9.4.2.2. Market Share & Forecast
        • 9.4.2.2.1. By Type
        • 9.4.2.2.2. By Route Of Administration
        • 9.4.2.2.3. By End User
    • 9.4.3. United Kingdom Pediatric Drugs Market Outlook
      • 9.4.3.1. Market Size & Forecast
        • 9.4.3.1.1. By Value
      • 9.4.3.2. Market Share & Forecast
        • 9.4.3.2.1. By Type
        • 9.4.3.2.2. By Route Of Administration
        • 9.4.3.2.3. By End User
    • 9.4.4. Italy Pediatric Drugs Market Outlook
      • 9.4.4.1. Market Size & Forecast
        • 9.4.4.1.1. By Value
      • 9.4.4.2. Market Share & Forecast
        • 9.4.4.2.1. By Type
        • 9.4.4.2.2. By Route Of Administration
        • 9.4.4.2.3. By End User
    • 9.4.5. Spain Pediatric Drugs Market Outlook
      • 9.4.5.1. Market Size & Forecast
        • 9.4.5.1.1. By Value
      • 9.4.5.2. Market Share & Forecast
        • 9.4.5.2.1. By Type
        • 9.4.5.2.2. By Route Of Administration
        • 9.4.5.2.3. By End User

10. Asia-Pacific Pediatric Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Route Of Administration
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. Policy & Regulatory Landscape
  • 10.4. Asia-Pacific: Country Analysis
    • 10.4.1. China Pediatric Drugs Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Type
        • 10.4.1.2.2. By Route Of Administration
        • 10.4.1.2.3. By End User
    • 10.4.2. India Pediatric Drugs Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Type
        • 10.4.2.2.2. By Route Of Administration
        • 10.4.2.2.3. By End User
    • 10.4.3. Japan Pediatric Drugs Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Type
        • 10.4.3.2.2. By Route Of Administration
        • 10.4.3.2.3. By End User
    • 10.4.4. South Korea Pediatric Drugs Market Outlook
      • 10.4.4.1. Market Size & Forecast
        • 10.4.4.1.1. By Value
      • 10.4.4.2. Market Share & Forecast
        • 10.4.4.2.1. By Type
        • 10.4.4.2.2. By Route Of Administration
        • 10.4.4.2.3. By End User
    • 10.4.5. Australia Pediatric Drugs Market Outlook
      • 10.4.5.1. Market Size & Forecast
        • 10.4.5.1.1. By Value
      • 10.4.5.2. Market Share & Forecast
        • 10.4.5.2.1. By Type
        • 10.4.5.2.2. By Route Of Administration
        • 10.4.5.2.3. By End User

11. South America Pediatric Drugs Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type
    • 11.2.2. Route Of Administration
    • 11.2.3. By End User
    • 11.2.4. By Country
  • 11.3. Policy & Regulatory Landscape
  • 11.4. South America: Country Analysis
    • 11.4.1. Brazil Pediatric Drugs Market Outlook
      • 11.4.1.1. Market Size & Forecast
        • 11.4.1.1.1. By Value
      • 11.4.1.2. Market Share & Forecast
        • 11.4.1.2.1. By Type
        • 11.4.1.2.2. By Route Of Administration
        • 11.4.1.2.3. By End User
    • 11.4.2. Argentina Pediatric Drugs Market Outlook
      • 11.4.2.1. Market Size & Forecast
        • 11.4.2.1.1. By Value
      • 11.4.2.2. Market Share & Forecast
        • 11.4.2.2.1. By Type
        • 11.4.2.2.2. By Route Of Administration
        • 11.4.2.2.3. By End User
    • 11.4.3. Colombia Pediatric Drugs Market Outlook
      • 11.4.3.1. Market Size & Forecast
        • 11.4.3.1.1. By Value
      • 11.4.3.2. Market Share & Forecast
        • 11.4.3.2.1. By Type
        • 11.4.3.2.2. By Route Of Administration
        • 11.4.3.2.3. By End User

12. Middle East and Africa Pediatric Drugs Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Type
    • 12.2.2. By Route Of Administration
    • 12.2.3. By End User
    • 12.2.4. By Country
  • 12.3. Policy & Regulatory Landscape
  • 12.4. MEA: Country Analysis
    • 12.4.1. South Africa Pediatric Drugs Market Outlook
      • 12.4.1.1. Market Size & Forecast
        • 12.4.1.1.1. By Value
      • 12.4.1.2. Market Share & Forecast
        • 12.4.1.2.1. By Type
        • 12.4.1.2.2. Route Of Administration
        • 12.4.1.2.3. By End User
    • 12.4.2. Saudi Arabia Pediatric Drugs Market Outlook
      • 12.4.2.1. Market Size & Forecast
        • 12.4.2.1.1. By Value
      • 12.4.2.2. Market Share & Forecast
        • 12.4.2.2.1. By Type
        • 12.4.2.2.2. By Route Of Administration
        • 12.4.2.2.3. By End User
    • 12.4.3. UAE Pediatric Drugs Market Outlook
      • 12.4.3.1. Market Size & Forecast
        • 12.4.3.1.1. By Value
      • 12.4.3.2. Market Share & Forecast
        • 12.4.3.2.1. By Type
        • 12.4.3.2.2. By Route Of Administration
        • 12.4.3.2.3. By End User

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

15. Porter's Five Force's Analysis

16. Global Pediatric Drugs Market: SWOT Analysis

17. List of Commercially Available Phage Types for Animal Health

18. Competitive Landscape

  • 18.1. Business Overview
  • 18.2. Company Snapshot
  • 18.3. Types & Services
  • 18.4. Financials (In case of listed companies)
  • 18.5. Recent Developments
  • 18.6. SWOT Analysis
    • 18.6.1. BioMarin
    • 18.6.2. Horizon Therapeutics plc
    • 18.6.3. Gilead Sciences Inc.
    • 18.6.4. Sumitomo Pharma Co., Ltd.
    • 18.6.5. Jazz Pharmaceuticals, Inc.
    • 18.6.6. GlaxoSmithKline plc.
    • 18.6.7. Abbott
    • 18.6.8. F. Hoffman La Roche, Ltd.
    • 18.6.9. Boehringer Ingelheim International GmbH
    • 18.6.10. Johnson & Johnson Services, Inc.
    • 18.6.11. Novartis AG
    • 18.6.12. Pfizer, Inc.

19. Strategic Recommendations

20. About Us & Disclaimer